
Sign up to save your podcasts
Or


Apparently Snap's IPO has a lot of people thinking about shorting stocks -- we answer a listener question and get into the nitty gritty risks of deciding to go short.
Apparently Snap's IPO has a lot of people thinking about shorting stocks -- we answer a listener question and get into the nitty gritty risks of deciding to go short.
Here's why Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.
Here's why Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.
Based on the latest network quality reports, most consumers will be happy with any of the Big Four wireless carriers, but one company continues to shake up the industry. We also provide an update on the struggle Bass Pro Shops is facing in its $4.5 deal with Cabela’s, before looking at the growing trend of delivery as a differentiator for restaurants.
Based on the latest network quality reports, most consumers will be happy with any of the Big Four wireless carriers, but one company continues to shake up the industry. We also provide an update on the struggle Bass Pro Shops is facing in its $4.5 deal with Cabela’s, before looking at the growing trend of delivery as a differentiator for restaurants.
The Oracle of Omaha just released his latest letter to the shareholders of Berkshire Hathaway. In this episode of Industry Focus, we talk about what he had to say.
From the publisher's feed